Bayesian forecasting for intravenous tobramycin dosing in adults with cystic fibrosis using one versus two serum concentrations in a dosing interval.
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic drug monitoring"
DOI: 10.1097/ftd.0000000000000900
Abstract: BACKGROUND Intravenous tobramycin treatment requires therapeutic drug monitoring (TDM) to ensure safety and efficacy when used for prolonged treatment, as in infective exacerbations of cystic fibrosis (CF). The 24-h area under the concentration-time curve (AUC24)… read more here.
Keywords: cystic fibrosis; auc24; tobramycin; intravenous tobramycin ... See more keywords